The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Keros Therapeutics Inc’s stock clocked out at $15.65, up 0.64% from its previous closing price of $15.55. In other words, the price has increased by $0.64 from its previous closing price. On the day, 1.26 million shares were traded. KROS stock price reached its highest trading level at $15.69 during the session, while it also had its lowest trading level at $15.15.
Ratios:
To gain a deeper understanding of KROS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.98. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $26.
On June 10, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 15 ’25 when Pontifax Management 4 G.P. (20 sold 4,787,331 shares for $17.75 per share. The transaction valued at 84,975,125 led to the insider holds 0 shares of the business.
ADAR1 Capital Management, LLC sold 5,389,264 shares of KROS for $95,659,436 on Oct 15 ’25. The 10% Owner now owns 0 shares after completing the transaction at $17.75 per share. On Sep 12 ’25, another insider, Rovaldi Christopher, who serves as the Affiliate of the company, bought 85,306 shares for $15.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 476793952 and an Enterprise Value of -36629772. As of this moment, Keros’s Price-to-Earnings (P/E) ratio for their current fiscal year is 49.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 16.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.05 while its Price-to-Book (P/B) ratio in mrq is 0.90. Its current Enterprise Value per Revenue stands at -0.157 whereas that against EBITDA is -21.908.
Stock Price History:
The Beta on a monthly basis for KROS is 0.90, which has changed by -0.7684978 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is 1.19%, while the 200-Day Moving Average is calculated to be 15.30%.
Shares Statistics:
It appears that KROS traded 663.07K shares on average per day over the past three months and 921710 shares per day over the past ten days. A total of 40.62M shares are outstanding, with a floating share count of 28.40M. Insiders hold about 6.77% of the company’s shares, while institutions hold 102.62% stake in the company. Shares short for KROS as of 1760486400 were 3817848 with a Short Ratio of 5.76, compared to 1757894400 on 4617384. Therefore, it implies a Short% of Shares Outstanding of 3817848 and a Short% of Float of 14.729999.
Earnings Estimates
A detailed examination of Keros Therapeutics Inc (KROS) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$1.4, with high estimates of -$1.4 and low estimates of -$1.4.
Analysts are recommending an EPS of between $2.46 and -$0.21 for the fiscal current year, implying an average EPS of $1.0. EPS for the following year is -$4.01, with 8.0 analysts recommending between -$0.75 and -$5.81.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $251.7M, while the lowest revenue estimate was $251.7M, resulting in an average revenue estimate of $251.7M. In the same quarter a year ago, actual revenue was $3.55M
